Loading
A phase 1/2 trial of HSK39775 Monotherapy in advanced solid tumours, run by Xizang Haisco Pharmaceutical Co., Ltd, now recruiting.
A Study for HSK39775 in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06314373 by Xizang Haisco Pharmaceutical Co., Ltd, with 243 participants planned, started 2024-03-07 and due to reach its primary completion in 2028-02-01. Interventions recorded: HSK39775 Monotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/